Stock listing
BOATS:KAPA Kairos Pharma, Ltd. Stock
US listing (BOATS) of Kairos Pharma, Ltd. · home listing NYSE American:KAPA
Follow Kairos Pharma, Ltd. into a list and get an email when it puts out news.
Home listing price · AMEX:KAPA
$0.474 USD -0.057 (-10.7%)
Close on Nov 2, 2026 · This listing has no price on 6ix; the price shown is the home listing's, AMEX:KAPA
- Day range
- $0.474 – $0.541 USDNov 2, 2026
- Volume
- 94,170 sharesNov 2, 2026
- Market cap
- $1.60M USDAt the close on Nov 2, 2026 · price × 3.39M shares outstanding
- 52-week range
- $0.474 – $7.700 USDLowest and highest trades, Nov 3, 2025 – Nov 2, 2026
- Traded on an average day
- $375,442 USDMedian day 50,900 shares · last 3 months, Aug 3, 2026 – Nov 2, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:KAPA · Home | $0.474 USD | -0.057 (-10.7%) | 94,170 | $0.541 | $0.541 | $0.474 | $0.530 | Close on Nov 2, 2026 |
Daily closes
Last 3 months, Aug 3, 2026 – Nov 2, 2026 · AMEX:KAPA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.474 | -0.057 | -10.7% | $0.541 | $0.541 | $0.474 | 94,170 | |
| $0.530 | -0.010 | -1.9% | $0.540 | $0.550 | $0.525 | 47,378 | |
| $0.540 | +0.017 | +3.2% | $0.536 | $0.576 | $0.525 | 116,415 | |
| $0.523 | -0.007 | -1.3% | $0.543 | $0.560 | $0.523 | 64,961 | |
| $0.530 | -0.006 | -1.1% | $0.525 | $0.553 | $0.525 | 33,960 | |
| $0.536 | -0.023 | -4.1% | $0.571 | $0.580 | $0.536 | 66,398 | |
| $0.559 | +0.015 | +2.8% | $0.544 | $0.590 | $0.530 | 112,300 | |
| $0.544 | -0.033 | -5.7% | $0.585 | $0.600 | $0.543 | 83,000 | |
| $0.577 | -0.007 | -1.2% | $0.566 | $0.617 | $0.565 | 164,100 | |
| $0.584 | +0.014 | +2.5% | $0.558 | $0.603 | $0.530 | 153,500 | |
| $0.570 | -0.031 | -5.2% | $0.624 | $0.628 | $0.522 | 233,800 | |
| $0.601 | -0.070 | -10.4% | $0.692 | $0.692 | $0.601 | 134,400 | |
| $0.671 | -0.072 | -9.7% | $0.721 | $0.731 | $0.656 | 253,200 | |
| $0.743 | -0.086 | -10.4% | $0.804 | $0.804 | $0.711 | 285,500 | |
| $0.829 | -0.003 | -0.4% | $0.832 | $0.839 | $0.783 | 155,300 | |
| $0.832 | +0.022 | +2.7% | $0.815 | $0.839 | $0.740 | 251,000 | |
| $0.810 | -0.150 | -15.6% | $0.911 | $1.004 | $0.783 | 637,800 | |
| $0.960 | +0.090 | +10.3% | $0.930 | $1.250 | $0.915 | 5,820,700 | |
| $0.870 | -0.280 | -24.3% | $1.090 | $1.140 | $0.848 | 1,098,900 | |
| $1.150 | -0.400 | -25.8% | $1.590 | $2.160 | $1.060 | 9,944,600 | |
| $1.550 | -0.010 | -0.6% | $1.550 | $1.590 | $1.520 | 19,100 | |
| $1.560 | 0.000 | 0.0% | $1.610 | $1.620 | $1.535 | 25,800 | |
| $1.560 | -0.080 | -4.9% | $1.590 | $1.650 | $1.470 | 79,100 | |
| $1.640 | -0.020 | -1.2% | $1.710 | $1.780 | $1.600 | 99,300 | |
| $1.660 | -0.020 | -1.2% | $1.680 | $1.755 | $1.640 | 50,900 | |
| $1.680 | -0.040 | -2.3% | $1.740 | $1.798 | $1.650 | 51,800 | |
| $1.720 | -0.050 | -2.8% | $1.770 | $1.780 | $1.720 | 42,300 | |
| $1.770 | +0.040 | +2.3% | $1.700 | $1.820 | $1.695 | 299,900 | |
| $1.730 | -0.050 | -2.8% | $1.750 | $1.778 | $1.700 | 63,400 | |
| $1.780 | -0.010 | -0.6% | $1.780 | $1.810 | $1.700 | 247,100 | |
| $1.790 | +0.060 | +3.5% | $1.750 | $1.800 | $1.700 | 126,400 | |
| $1.730 | -0.080 | -4.4% | $1.810 | $1.840 | $1.720 | 168,700 | |
| $1.810 | 0.000 | 0.0% | $1.840 | $1.840 | $1.780 | 33,400 | |
| $1.810 | -0.040 | -2.2% | $1.840 | $1.840 | $1.810 | 5,300 | |
| $1.850 | +0.010 | +0.5% | $1.790 | $1.890 | $1.760 | 37,600 | |
| $1.840 | +0.082 | +4.7% | $1.700 | $1.860 | $1.700 | 53,500 | |
| $1.758 | +0.078 | +4.6% | $1.687 | $1.765 | $1.670 | 33,000 | |
| $1.680 | +0.020 | +1.2% | $1.690 | $1.730 | $1.621 | 32,600 | |
| $1.660 | -0.110 | -6.2% | $1.760 | $1.800 | $1.660 | 81,400 | |
| $1.770 | -0.070 | -3.8% | $1.850 | $1.890 | $1.770 | 173,400 | |
| $1.840 | +0.170 | +10.2% | $1.670 | $1.910 | $1.660 | 302,400 | |
| $1.670 | +0.090 | +5.7% | $1.550 | $1.690 | $1.550 | 47,600 | |
| $1.580 | -0.070 | -4.2% | $1.610 | $1.650 | $1.510 | 105,300 | |
| $1.650 | -0.030 | -1.8% | $1.720 | $1.850 | $1.520 | 76,300 | |
| $1.680 | +0.021 | +1.3% | $1.687 | $1.750 | $1.638 | 7,559 | |
| $1.659 | -0.028 | -1.7% | $1.708 | $1.743 | $1.624 | 4,543 | |
| $1.687 | -0.133 | -7.3% | $1.883 | $1.883 | $1.575 | 8,967 | |
| $1.820 | +0.084 | +4.8% | $1.764 | $1.897 | $1.729 | 13,694 | |
| $1.736 | +0.112 | +6.9% | $1.701 | $1.750 | $1.638 | 7,292 | |
| $1.624 | -0.406 | -20.0% | $1.806 | $1.806 | $1.540 | 35,200 | |
| $2.030 | -0.035 | -1.7% | $2.030 | $2.107 | $2.023 | 6,073 | |
| $2.065 | -0.105 | -4.8% | $2.163 | $2.240 | $2.044 | 5,073 | |
| $2.170 | 0.000 | 0.0% | $2.170 | $2.205 | $2.107 | 3,967 | |
| $2.170 | -0.105 | -4.6% | $2.240 | $2.268 | $2.170 | 4,512 | |
| $2.275 | -0.112 | -4.7% | $2.387 | $2.401 | $2.240 | 12,449 | |
| $2.387 | -0.133 | -5.3% | $2.443 | $2.471 | $2.331 | 3,761 | |
| $2.520 | +0.035 | +1.4% | $2.380 | $2.520 | $2.380 | 3,073 | |
| $2.485 | -0.056 | -2.2% | $2.471 | $2.520 | $2.401 | 5,045 | |
| $2.541 | +0.091 | +3.7% | $2.415 | $2.541 | $2.380 | 8,835 | |
| $2.450 | -0.252 | -9.3% | $2.583 | $2.632 | $2.450 | 18,273 | |
| $2.702 | -0.028 | -1.0% | $2.772 | $2.842 | $2.590 | 12,741 | |
| $2.730 | +0.420 | +18.2% | $2.275 | $2.772 | $2.275 | 46,431 | |
| $2.310 | +0.035 | +1.5% | $2.240 | $2.401 | $2.219 | 18,318 | |
| $2.275 | +0.105 | +4.8% | $2.163 | $2.373 | $2.163 | 9,753 | |
| $2.170 | +0.028 | +1.3% | $2.107 | $2.240 | $2.065 | 8,847 |
- Ticker
- BOATS:KAPA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Oct 6, 2026
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
Latest deck · Sep 14, 2026
Investor Presentation (September 2026)
Investor deck · 25 slides
Latest news
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
Oct 6, 2026
Closed $1.15 (-25.8%) on Oct 6, 2026
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 9, 2026
Closed $1.66 (-6.2%) on Sep 9, 2026
Kairos Pharma Announces 1-for-7 Reverse Stock Split
Aug 21, 2026
Closed $1.62 (-20.0%) on Aug 24, 2026
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
Jul 22, 2026
Closed $2.19 (-12.6%) on Jul 22, 2026
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
Jul 15, 2026
Closed $2.23 (-6.5%) on Jul 15, 2026
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
Jun 4, 2026
Closed $3.26 (+0.9%) on Jun 4, 2026
Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award
May 14, 2026
Closed $3.44 (+6.0%) on May 14, 2026
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
May 13, 2026
Closed $3.25 (-4.3%) on May 13, 2026
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings
May 8, 2026
Closed $3.71 (-5.4%) on May 11, 2026
Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation
Apr 15, 2026
Closed $4.20 (0.0%) on Apr 15, 2026
Decks
Investor Presentation (September 2026)
Investor deck · 25 slides · Sep 14, 2026
Investor Presentation (May 2026)
Investor deck · 32 slides · May 18, 2026
Investor Presentation (2026)
Investor deck · 25 slides · 2026
Corporate Update (September 2025)
Corporate update · 7 slides · Sep 18, 2025
Kairos Pharma, Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 28 in all · newest Oct 6, 2026 · oldest 2025
- Decks
- 5 decks · latest Sep 14, 2026
Where Kairos Pharma, Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:KAPA · Home listing | NYSE American | United States | USD |
| BOATS:KAPA · This page | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Kairos Pharma, Ltd.